Deep product pipeline of T2MR applications in development

T2 Biosystems has multiple applications currently in development that may enable breakthroughs in providing more rapid and accurate therapy to patients. All are focused on high-value healthcare ailments where solutions can serve a dual role: saving lives while reducing costs. Due to T2MR technology's advantage of detecting directly from patient blood samples, there is an opportunity for significant clinical advantages and market impact.

In addition to our FDA-cleared T2Candida Panel and T2Dx Instrument, new products in the pipeline include additional sepsis, hemostasis and Lyme disease applications.

T2Bacteria™ Panel – Rapid bacteria sepsis panel requiring no blood culture and run on the FDA-cleared T2Dx Instrument

T2HemoStat™ Panel Comprehensive hemostasis profiling for trauma patients at the point of care

T2Plex™ Instrument  Compact, fully-integrated instrument for providing rapid hemostasis measurements at the point of care 

T2Lyme™ Panel – T2 Biosystems and Canon US Life Sciences have partnered to develop a rapid diagnostic for Lyme disease

The T2Dx Instrument and T2Candida Panel have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.